Merck & Co., Inc. is 154.1x more valuable than Trevi Therapeutics, Inc. by market capitalization ($293.16 B vs $1.90 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TRVI | MRK |
|---|---|---|
| Market cap | $1.90 B | $293.16 B |
| US-listed rank | #2132 | #44 |
| Revenue (latest FY) | - | $65.01B |
| Net income (latest FY) | -$42.76M | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 524 | 996 |
Merck & Co., Inc. is 154.1x more valuable than Trevi Therapeutics, Inc. by market capitalization ($293.16 B vs $1.90 B).
Full pages: Trevi Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.